Nishi Kothari1, Jamie K Teer2, Andrea M Abbott3, Thejal Srikumar4, Yonghong Zhang2, Sean J Yoder5, Andrew S Brohl6,7, Richard D Kim1, Damon R Reed6,8,7, David Shibata9. 1. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 3. Department of Surgery, Medical University of South Carolina, Charleston, South Carolina. 4. University of South Florida Morsani College of Medicine, Tampa, Florida. 5. Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 6. Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 7. Chemical Biology and Molecular Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 8. Adolescent and Young Adult Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 9. Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee.
Abstract
BACKGROUND: The incidence and outcomes of patients with colorectal cancer (CRC) varies by age. Younger patients tend to have sporadic cancers that are not detected by screening and worse survival. To understand whether genetic differences exist between age cohorts, the authors sought to characterize unique genetic alterations in patients with CRC. METHODS: In total, 283 patients who were diagnosed with sporadic CRC between 1998 and 2010 were identified and divided by age into 2 cohorts-ages ≤45 years (the younger cohort) and ≥65 years (the older cohort)-and targeted exome sequencing was performed. The Fisher exact test was used to detect differences in mutation frequencies between the 2 groups. Whole exome sequencing was performed on 21 additional younger patient samples for validation. Findings were confirmed in The Cancer Genome Atlas CRC data set. RESULTS: In total, 246 samples were included for final analysis (195 from the older cohort and 51 from the younger cohort). Mutations in the FBXW7 gene were more common in the younger cohort (27.5% vs 9.7%; P = .0022) as were mutations in the proofreading domain of polymerase ε catalytic subunit (POLE) (9.8% vs 1%; P = .0048). There were similar mutation rates between cohorts with regard to TP53 (64.7% vs 61.5%), KRAS (43.1% vs 46.2%), and APC (60.8% vs 73.8%). BRAF mutations were numerically more common in the older cohort, although the difference did not reach statistical significance (2% vs 9.7%; P = .082). CONCLUSIONS: In this retrospective study, a unique genetic profile was identified for younger patients who have CRC compared with patients who are diagnosed at an older age. These findings should be validated in a larger study and could have an impact on future screening and treatment modalities for younger patients with CRC. Cancer 2016.
BACKGROUND: The incidence and outcomes of patients with colorectal cancer (CRC) varies by age. Younger patients tend to have sporadic cancers that are not detected by screening and worse survival. To understand whether genetic differences exist between age cohorts, the authors sought to characterize unique genetic alterations in patients with CRC. METHODS: In total, 283 patients who were diagnosed with sporadic CRC between 1998 and 2010 were identified and divided by age into 2 cohorts-ages ≤45 years (the younger cohort) and ≥65 years (the older cohort)-and targeted exome sequencing was performed. The Fisher exact test was used to detect differences in mutation frequencies between the 2 groups. Whole exome sequencing was performed on 21 additional younger patient samples for validation. Findings were confirmed in The Cancer Genome Atlas CRC data set. RESULTS: In total, 246 samples were included for final analysis (195 from the older cohort and 51 from the younger cohort). Mutations in the FBXW7 gene were more common in the younger cohort (27.5% vs 9.7%; P = .0022) as were mutations in the proofreading domain of polymerase ε catalytic subunit (POLE) (9.8% vs 1%; P = .0048). There were similar mutation rates between cohorts with regard to TP53 (64.7% vs 61.5%), KRAS (43.1% vs 46.2%), and APC (60.8% vs 73.8%). BRAF mutations were numerically more common in the older cohort, although the difference did not reach statistical significance (2% vs 9.7%; P = .082). CONCLUSIONS: In this retrospective study, a unique genetic profile was identified for younger patients who have CRC compared with patients who are diagnosed at an older age. These findings should be validated in a larger study and could have an impact on future screening and treatment modalities for younger patients with CRC. Cancer 2016.
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Shahab Akhoondi; Dahui Sun; Natalie von der Lehr; Sophia Apostolidou; Kathleen Klotz; Alena Maljukova; Diana Cepeda; Heidi Fiegl; Dimitra Dafou; Dimitra Dofou; Christian Marth; Elisabeth Mueller-Holzner; Martin Corcoran; Markus Dagnell; Sepideh Zabihi Nejad; Babak Noori Nayer; Mohammad Reza Zali; Johan Hansson; Susanne Egyhazi; Fredrik Petersson; Per Sangfelt; Hans Nordgren; Dan Grander; Steven I Reed; Martin Widschwendter; Olle Sangfelt; Charles Spruck Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson Journal: Nat Genet Date: 2012-12-23 Impact factor: 38.330
Authors: Theresa H M Keegan; David J Press; Li Tao; Mindy C DeRouen; Allison W Kurian; Christina A Clarke; Scarlett L Gomez Journal: Breast Cancer Res Date: 2013 Impact factor: 6.466
Authors: Mohamed E Salem; Francesca Battaglin; Richard M Goldberg; Alberto Puccini; Anthony F Shields; David Arguello; W Michael Korn; John L Marshall; Axel Grothey; Heinz-Josef Lenz Journal: Oncologist Date: 2019-12-17
Authors: Po-Hong Liu; Kana Wu; Kimmie Ng; Ann G Zauber; Long H Nguyen; Mingyang Song; Xiaosheng He; Charles S Fuchs; Shuji Ogino; Walter C Willett; Andrew T Chan; Edward L Giovannucci; Yin Cao Journal: JAMA Oncol Date: 2019-01-01 Impact factor: 31.777
Authors: Alberto Puccini; Heinz-Josef Lenz; John L Marshall; David Arguello; Derek Raghavan; W Michael Korn; Benjamin A Weinberg; Kelsey Poorman; Arielle L Heeke; Philip A Philip; Anthony F Shields; Richard M Goldberg; Mohamed E Salem Journal: Oncologist Date: 2018-07-17
Authors: James V Tricoli; Lisa A Boardman; Rajesh Patidar; Sivasish Sindiri; Jin S Jang; William D Walsh; Paul M McGregor; Corinne E Camalier; Michele G Mehaffey; Wayne L Furman; Armita Bahrami; P Mickey Williams; Chih-Jian Lih; Barbara A Conley; Javed Khan Journal: Cancer Date: 2017-11-30 Impact factor: 6.860
Authors: Damon R Reed; Benjamin Oshrine; Christie Pratt; Olivia Fridgen; Cathy Elstner; Leila Wilson; Hatem Soliman; Marie C Lee; Howard L McLeod; Bijal Shah; Kristine A Donovan; Smitha Pabbathi; Mary Turney; Odion Binitie; Christine Healy; Michael Nieder; Peter H Shaw; Andrew Galligan; G Douglas Letson; Marilyn Stern; Gwendolyn P Quinn; Simon Davies Journal: J Adolesc Young Adult Oncol Date: 2017-08-04 Impact factor: 2.223